The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)

IL‐6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL‐6, and summarizes t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Wanhai, Zhang, Li, Dai, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Mini Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113041/
https://www.ncbi.nlm.nih.gov/pubmed/32043828
http://dx.doi.org/10.1111/1759-7714.13341
_version_ 1783513590973595648
author Ke, Wanhai
Zhang, Li
Dai, Yan
author_facet Ke, Wanhai
Zhang, Li
Dai, Yan
author_sort Ke, Wanhai
collection PubMed
description IL‐6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL‐6, and summarizes the diagnostic and prognostic value of IL‐6 level. Anti‐IL‐6 therapy does not affect the effect of immunocheckpoint inhibitors (ICIs), but enhances its anticancer function, which may be the treatment option for immune‐related adverse events (irAEs) in the future. Therefore, IL‐6 may be a therapeutic target for the treatment of NSCLC.
format Online
Article
Text
id pubmed-7113041
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-71130412020-04-02 The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs) Ke, Wanhai Zhang, Li Dai, Yan Thorac Cancer Mini Reviews IL‐6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL‐6, and summarizes the diagnostic and prognostic value of IL‐6 level. Anti‐IL‐6 therapy does not affect the effect of immunocheckpoint inhibitors (ICIs), but enhances its anticancer function, which may be the treatment option for immune‐related adverse events (irAEs) in the future. Therefore, IL‐6 may be a therapeutic target for the treatment of NSCLC. John Wiley & Sons Australia, Ltd 2020-02-11 2020-04 /pmc/articles/PMC7113041/ /pubmed/32043828 http://dx.doi.org/10.1111/1759-7714.13341 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Mini Reviews
Ke, Wanhai
Zhang, Li
Dai, Yan
The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_full The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_fullStr The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_full_unstemmed The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_short The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
title_sort role of il‐6 in immunotherapy of non‐small cell lung cancer (nsclc) with immune‐related adverse events (iraes)
topic Mini Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113041/
https://www.ncbi.nlm.nih.gov/pubmed/32043828
http://dx.doi.org/10.1111/1759-7714.13341
work_keys_str_mv AT kewanhai theroleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT zhangli theroleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT daiyan theroleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT kewanhai roleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT zhangli roleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes
AT daiyan roleofil6inimmunotherapyofnonsmallcelllungcancernsclcwithimmunerelatedadverseeventsiraes

Ejemplares similares